What experience has taught us about protease inhibitors, protease resistance, and protease sequencing
PAUL A. VOLBERDING, M.D.
Because resistance will develop over time to all of the protease inhibitors, clinicians should think in terms of successive regimens
STEVEN G. DEEKS, M.D., AND JAMES O. KAHN, M.D.
The clinical significance of surrogate markers: CD4 counts and HIV RNA levels do predict rate of disease progression ... In treating MAC, less may be more: Adding clofazimine to clarithromycin and ethambutol does not improve symptoms or survival ... Is resistance always a bad thing? Repeated mutation may eventually render HIV ineffective ... Enhancing saquinavir levels with ritonavir: Two-drug combination overcomes chief limitation of saquinavir, its low bioavailability ... Clinton Administration proposes extending Medicaid benefits to people with asymptomatic HIV: Policy change will make protease inhibitors available to thousands who have not yet developed AIDS ... A novel NNRTI with activity against resistant strains: Another entrant in a rapidly expanding field ... New macrolide inhibits late-stage HIV replication: First compound in its class shows strong in vitro antiretroviral activity ... Approval sought for new formulation of saquinavir ...
PULL OUT AND SAVE
Steps that can be taken by healthcare professionals, working in partnership with their patients, to increase compliance with multidrug antiretroviral regimens
With the advent of multidrug regimens, adherence to therapy is more than a challenge, it is a necessity
MARGARET A. CHESNEY, PH.D.
Potent and promising new drugs will soon be available to combat HIV infection
HAROLD A. KESSLER, M.D.
This article was provided by San Francisco General Hospital. It is a part of the publication HIV Newsline.